Amended Current Report Filing (8-k/a)
November 22 2019 - 8:26AM
Edgar (US Regulatory)
0000203527
false
0000203527
2019-10-22
2019-10-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported)
|
October
23, 2019
|
VARIAN MEDICAL SYSTEMS, INC.
|
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
1-7598
|
94-2359345
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission File
Number)
|
(IRS Employer
Identification No.)
|
3100 Hansen Way, Palo Alto, CA
|
94304-1030
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant's telephone number, including area code
|
(650) 493-4000
|
Not Applicable
|
(Former Name or Former Address, if Changed Since Last Report)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
|
Trading Symbol(s)
|
Name of each exchange on which registered:
|
Common Stock, $1 par value
|
VAR
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 2.02.
|
Results of Operation and Financial Condition.
|
On
October 23, 2019, Varian Medical Systems, Inc. (the "Company") filed a Current Report on Form 8-K that incorporated by
reference into such report, as Exhibit 99.1, a press release dated October 23, 2019 reporting the Company’s preliminary results
for the fourth quarter and fiscal year ended September 27, 2019.
On
November 21, 2019, the Company issued a press release updating (the “Updating Press Release”) its previously reported
results to take into account the fair value increase of certain contingent consideration. Furnished herewith as Exhibit 99.1 and
incorporated by reference herein is a copy of the Updating Press Release. The Company is filing this Current Report on Form 8-K/A
to update the Company’s results for the fourth quarter and fiscal year ended September 27, 2019.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Varian Medical Systems, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ John W. Kuo
|
|
Name:
|
John W. Kuo
|
|
Title:
|
Senior Vice President, General Counsel and Corporate Secretary
|
Dated: November 21, 2019
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Varian Medical System (NYSE:VAR)
Historical Stock Chart
From Apr 2023 to Apr 2024